Back to search

Article

Clinical Validation Of ANKRD36 Mutations As A Novel Biomarker For Monitoring Early Progression and Timely Clinical Interventions In Blast Crisis CML

2024-01-03

Abstract excerpt

<h4>Background: </h4> Chronic Myeloid Leukemia (CML) is initiated in the bone marrow due to the chromosomal translocation t(9;22), resulting in the fusion oncogene BCR-ABL. Tyrosine kinase inhibitors (TKIs) targeting BCR-ABL have transformed fatal CML into an almost curable disease. However, TKIs lose efficacy during disease progression, and the mechanism of CML progression remains to be fully understood. Addition...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
bed4c991-8c97-516c-9579-2f22d22648fa
DOI
10.20944/preprints202401.0239.v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Clinical Validation Of ANKRD36 Mutations As A Novel Biomarker For Monitoring Early Progression and Timely Clinical Interventions In Blast Crisis CMLDOI 10.20944/preprints202401.0239.v1
Investigations on Clinical Validation of mutated ANKRD36 as a Novel Molecular Biomarker for Monitoring Early Progression and Timely Therapeutic Interventions in Blast Crisis CMLSemantic proximity
Integrated Genomic Analysis Identifies ANKRD36 Gene as a Novel and Common Biomarker of Disease Progression in Chronic Myeloid LeukemiaSemantic proximity
Integrated Genomic Analysis Identifies ANKRD36 Gene as a Novel and Common Biomarker of Disease Progression in Chronic Myeloid LeukemiaSemantic proximity
A retrospective case-control study for Clinical Validation of mutated ZNF208 as a novel biomarker of fatal blast crisis in Chronic Myeloid LeukemiaSemantic proximity
Next-generation DNA sequencing identifies mutated FANCD2 Gene as a novel Biomarker for monitoring early disease progression and timely therapeutic interventions in advanced phase Chronic Myeloid Leukemia patientsSemantic proximity
Next-Generation DNA Sequencing Identifies Mutated FANCD2 Gene as a Novel Biomarker for Monitoring Early Disease Progression and Timely Therapeutic Interventions in Advanced Phase Chronic Myeloid Leukemia PatientsSemantic proximity
Clinical Significance of the S348l Mutation in BCR-ABL as a Dominant Variant in Indonesian CML Patients Under Tyrosine Kinase Inhibitor Therapy: A Cohort Study.Semantic proximity
Investigations on druggable gene mutations related to AML/ALL lineage genes in Advanced Phases of CML: Implications in patient-tailored therapy of blast crisis CML in TKI eraSemantic proximity
Identification of Prognostic and Susceptibility Markers in Chronic Myeloid Leukemia Using Next Generation Sequencing.Semantic proximity
Current trends in molecular diagnostics of chronic myeloid leukemiaSemantic proximity
Repositioning of FDA-approved anti-cancer drugs for fatal blast crisis CML by integrated high-throughput genomic and artificial intelligence-based drug discovery analyses of pan-leukemic genetic abnormalities: Implications in post-COVID-19 eraSemantic proximity
Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemiaSemantic proximity
Select a neighboring publication to make it the new centre.